Recent data indicates that retatrutide, a innovative medication, might represent a major advance in size loss . This therapy combines the effects of a GLP-1 receptor and a GIP analog, possibly offering a greater benefit than available approaches . Clinical assessments have shown positive outcomes, including considerable declines in size and advance